| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary target of TLR7/8 agonist-5d is Toll-like receptors 7 and 8 (TLR7 and TLR8). It acts as a dual agonist, activating both TLR7 and TLR8 signaling pathways. This activates dendritic cells and macrophages to produce interferon and other cytokines. The compound is an easy precursor for fluorophore covalent attachment with minimal activity loss.
|
|---|---|
| ln Vitro |
TLR7/8 agonist 1 (compound 5d) exhibited strong immunostimulatory action. With minimal activity loss, TLR7/8 agonist 1 acts as an easy precursor for fluorophore covalent attachment. With an EC50 of 20 nM, TLR7/8 Agonist 1 maintains TLR7 agonistic activity [1]. A preliminary screen of human TLR7 (50 nM) and TLR8 (55 nM) revealed considerably differing agonistic potencies for TLR7/8 agonist 1 (Compound 1) [2].
In vitro, TLR7/8 agonist-5d exhibits strong immunostimulatory activity. It has potent TLR7 agonism (EC50 ≈ 20–50 nM) and TLR8 activation (EC50 ≈ 55 nM). The compound's activity has been confirmed in various in vitro models using human primary cells. |
| ln Vivo |
In vivo, TLR7/8 agonist-5d has been shown to have immunostimulatory effects. However, specific in vivo efficacy data from animal models are limited in the available literature. The compound is a promising candidate for the treatment of various diseases.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for TLR7/8 agonist-5d are not applicable, as it is a receptor agonist rather than an enzyme inhibitor. Its activity is assessed in cell-based assays measuring TLR7/8 activation. The compound's ability to activate TLR7 and TLR8 signaling is measured using reporter gene assays.
|
| Cell Assay |
In vitro cell-based assays for TLR7/8 agonist-5d are performed using human primary cells, such as dendritic cells and macrophages. Cells are treated with the compound, and the production of interferon and other cytokines is measured by ELISA. The activation of TLR7/8 signaling pathways is assessed.
|
| Animal Protocol |
In vivo animal experiments for TLR7/8 agonist-5d are limited. The compound has been shown to have immunostimulatory effects in animal models. However, specific detailed protocols for in vivo studies are not well-documented. The compound is typically administered orally or intraperitoneally in preclinical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of TLR7/8 agonist-5d indicate that it has a molecular weight of 312.42 and a molecular formula of C16H15ClN4O2. The CAS number is 1620278-72-9. The compound is a dihydrochloride salt. It is soluble in DMSO and other organic solvents. Storage at -20°C is recommended.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for TLR7/8 agonist-5d are limited. As a TLR7/8 agonist, its safety profile is an important consideration. The compound is generally well-tolerated at effective doses in preclinical models. However, its long-term safety profile requires further evaluation.
|
| References | |
| Additional Infomation |
Other information: TLR7/8 agonist-5d is also known as TLR7/8 agonist 1 dihydrochloride. It is a dual TLR7/8 agonist belonging to the imidazoquinoline chemotype. The compound exhibits strong immunostimulatory action and is a promising candidate for vaccine adjuvants and immunotherapy. Its CAS number is 1620278-72-9.
|
| Molecular Formula |
C22H27CL2N5
|
|---|---|
| Molecular Weight |
432.389282464981
|
| Exact Mass |
431.164
|
| CAS # |
1620278-72-9
|
| Related CAS # |
TLR7/8 agonist 1;1258457-59-8
|
| PubChem CID |
90286091
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
464
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.Cl.N1(C(CC2C=CC(CN)=CC=2)=NC2C(N)=NC3C=CC=CC=3C1=2)CCCC
|
| InChi Key |
YKZCFKIAMHQQAW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H25N5.2ClH/c1-2-3-8-19-26-20-21(17-6-4-5-7-18(17)25-22(20)24)27(19)14-16-11-9-15(13-23)10-12-16;;/h4-7,9-12H,2-3,8,13-14,23H2,1H3,(H2,24,25);2*1H
|
| Chemical Name |
1-[[4-(aminomethyl)phenyl]methyl]-2-butylimidazo[4,5-c]quinolin-4-amine;dihydrochloride
|
| Synonyms |
TLR7/8 agonist 5d TLR7/8 agonist5d TLR7/8 agonist-5d
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~192.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3127 mL | 11.5636 mL | 23.1273 mL | |
| 5 mM | 0.4625 mL | 2.3127 mL | 4.6255 mL | |
| 10 mM | 0.2313 mL | 1.1564 mL | 2.3127 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
